Tags

Type your tag names separated by a space and hit enter

Aerosolized polymerized type I collagen reduces airway inflammation and remodelling in a guinea pig model of allergic asthma.
Lung. 2010 Apr; 188(2):97-105.LUNG

Abstract

Collagen-polyvinylpyrrolidone (Collagen-PVP) has been demonstrated to elicit immunomodulatory properties in different chronic inflammatory diseases. Nevertheless, its effects on asthma are still unknown. We have evaluated whether collagen-PVP could modulate airway inflammation and remodelling in a guinea pig model of allergic asthma. Sensitized guinea pigs were challenged with the allergen (ovalbumin) six times (at 10-day intervals). From the third challenge on, animals were treated every 5 days with saline aerosols containing 0.16, 0.33, or 0.66 mg/ml of collagen-PVP (n = 5, respectively). Some guinea pigs, sensitized and challenged with saline as well as treated with 0 or 0.66 mg/ml collagen-PVP, were included in the study as control (n = 7) and sham groups (n = 5), respectively. From the first challenge on, ovalbumin induced a transient airway obstruction, measured by barometric plethysmography, which was not modified by collagen-PVP treatments. After the last allergen challenge, guinea pigs were anesthetized to obtain bronchoalveolar lavage (BAL) and the left lung caudal lobe. As expected, BAL cell count from allergen-challenged guinea pigs showed abundant neutrophils and eosinophils, as well as numerous tumor necrosis factor (TNF)-alpha-expressing granulocytes and macrophages in airway wall (determined by immunohistochemical assay). Neutrophilia and TNF-alpha-expressing leukocytes, from collagen-PVP treated animals, diminished from 0.16 mg/ml, and eosinophilia from 0.66 mg/ml of collagen-PVP doses. Histological changes induced by allergen challenges include thickening of connective tissue below airway epithelium and vascular wall widening of airway adjacent vessels; these changes were reduced by collagen-PVP treatment. Collagen-PVP seems to have anti-inflammatory and antifibrotic properties in this guinea pig asthma model.

Authors+Show Affiliations

Departamento de Biología Celular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Insurgentes Sur 3700, CP 04510 Mexico, DF, Mexico.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19998041

Citation

Moreno-Alvarez, Paola, et al. "Aerosolized Polymerized Type I Collagen Reduces Airway Inflammation and Remodelling in a Guinea Pig Model of Allergic Asthma." Lung, vol. 188, no. 2, 2010, pp. 97-105.
Moreno-Alvarez P, Sánchez-Guerrero E, Martínez-Cordero E, et al. Aerosolized polymerized type I collagen reduces airway inflammation and remodelling in a guinea pig model of allergic asthma. Lung. 2010;188(2):97-105.
Moreno-Alvarez, P., Sánchez-Guerrero, E., Martínez-Cordero, E., Hernández-Pando, R., Campos, M. G., Cetina, L., & Bazán-Perkins, B. (2010). Aerosolized polymerized type I collagen reduces airway inflammation and remodelling in a guinea pig model of allergic asthma. Lung, 188(2), 97-105. https://doi.org/10.1007/s00408-009-9202-2
Moreno-Alvarez P, et al. Aerosolized Polymerized Type I Collagen Reduces Airway Inflammation and Remodelling in a Guinea Pig Model of Allergic Asthma. Lung. 2010;188(2):97-105. PubMed PMID: 19998041.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aerosolized polymerized type I collagen reduces airway inflammation and remodelling in a guinea pig model of allergic asthma. AU - Moreno-Alvarez,Paola, AU - Sánchez-Guerrero,Edgar, AU - Martínez-Cordero,Erasmo, AU - Hernández-Pando,Rogelio, AU - Campos,María G, AU - Cetina,Lucely, AU - Bazán-Perkins,Blanca, Y1 - 2009/12/09/ PY - 2009/07/08/received PY - 2009/11/13/accepted PY - 2009/12/10/entrez PY - 2009/12/10/pubmed PY - 2010/6/11/medline SP - 97 EP - 105 JF - Lung JO - Lung VL - 188 IS - 2 N2 - Collagen-polyvinylpyrrolidone (Collagen-PVP) has been demonstrated to elicit immunomodulatory properties in different chronic inflammatory diseases. Nevertheless, its effects on asthma are still unknown. We have evaluated whether collagen-PVP could modulate airway inflammation and remodelling in a guinea pig model of allergic asthma. Sensitized guinea pigs were challenged with the allergen (ovalbumin) six times (at 10-day intervals). From the third challenge on, animals were treated every 5 days with saline aerosols containing 0.16, 0.33, or 0.66 mg/ml of collagen-PVP (n = 5, respectively). Some guinea pigs, sensitized and challenged with saline as well as treated with 0 or 0.66 mg/ml collagen-PVP, were included in the study as control (n = 7) and sham groups (n = 5), respectively. From the first challenge on, ovalbumin induced a transient airway obstruction, measured by barometric plethysmography, which was not modified by collagen-PVP treatments. After the last allergen challenge, guinea pigs were anesthetized to obtain bronchoalveolar lavage (BAL) and the left lung caudal lobe. As expected, BAL cell count from allergen-challenged guinea pigs showed abundant neutrophils and eosinophils, as well as numerous tumor necrosis factor (TNF)-alpha-expressing granulocytes and macrophages in airway wall (determined by immunohistochemical assay). Neutrophilia and TNF-alpha-expressing leukocytes, from collagen-PVP treated animals, diminished from 0.16 mg/ml, and eosinophilia from 0.66 mg/ml of collagen-PVP doses. Histological changes induced by allergen challenges include thickening of connective tissue below airway epithelium and vascular wall widening of airway adjacent vessels; these changes were reduced by collagen-PVP treatment. Collagen-PVP seems to have anti-inflammatory and antifibrotic properties in this guinea pig asthma model. SN - 1432-1750 UR - https://www.unboundmedicine.com/medline/citation/19998041/Aerosolized_polymerized_type_I_collagen_reduces_airway_inflammation_and_remodelling_in_a_guinea_pig_model_of_allergic_asthma_ L2 - https://dx.doi.org/10.1007/s00408-009-9202-2 DB - PRIME DP - Unbound Medicine ER -